Duane H. Hamilton, Ph.D.
Dr. Hamilton is a Staff Scientist and Head of the Immunotherapeutics Group in the Laboratory of Tumor Immunology and Biology, NCI. He received his Ph.D. in Immunology from the University of Saskatchewan, Canada. Dr. Hamilton's research interests include cellular immunotherapy; tumor immunology; cancer vaccines. The Immunotherapeutics Group is working to identify, and characterize novel epitopes and neoepitopes uniquely expressed by human tumors. We are involved in studying techniques to enhance the antigenicity of these tumor-associated neoepitopes, with an aim to enhance the effectiveness of cancer-targeting vaccines.
1) cancer immunotherapy, 2) CTL epitopes
The main goal of our research program is to identify and characterize tumor-specific antigens and neoepitopes. We are evaluating techniques to identify tumor antigens unique to a patient’s own tumor. It is our belief that vaccinating patients with neoepitopes uniquely expressed by their tumor will improve the breadth of anti-tumor immunity generated by our vaccine platforms, and result in greater immunological control of tumor growth.
Selected Key Publications
Targeting estrogen receptor signaling with fulvestrant enhances immune and chemotherapy-mediated cytotoxicity of human lung cancer.Clin Cancer Res. 22: 6204-16, 2016. [ Journal Article ]
WEE1 inhibition alleviates resistance to immune attack of tumor cells undergoing epithelial-mesenchymal transition.Cancer Res. 74: 2510-2519, 2014. [ Journal Article ]
- Adv Cancer Res. 128: 69-93, 2015. [ Journal Article ]
An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition.OncoImmunol. 3: e27220, 2014. [ Journal Article ]
Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas (Review).Semin Oncol. 39: 358-366, 2012. [ Journal Article ]
Dr. Duane Hamilton received his Ph.D. degree in Immunology from the University of Saskatchewan, Canada, in 2007. He subsequently joined the NIH as a Postdoctoral Fellow in the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, and was appointed as a Staff Scientist in 2015. Dr. Hamilton’s current research focuses on the identification and characterization of novel tumor-specific antigens and neoepitopes that can help the immune system to target and eliminate cancer cells.
|Karin Le-Shi Lee Ph.D.||Postdoctoral Fellow (CRTA)|
|Laura Minang||Biologist (Contr)|